Evaluating whole fruit feijoa powder for type 2 diabetes risk prevention: the FERDINAND study

Mohamed I.A.[a,b], Sequeira-Bisson I.R.[a,b,c], Poppitt, S.D.[a,b,d], Miles-Chan J.L[a,b,c]

a: Human Nutrition Unit, School of Biological Sciences, University of Auckland, Auckland, New Zealand.

b: High Value Nutrition National Science Challenge, Auckland, New Zealand.

c: Riddet Institute, Palmerston North, New Zealand.

d: Department of Medicine, University of Auckland, Auckland, New Zealand.

***Corresponding Author:**

A/Prof Jennifer Miles-Chan

Human Nutrition Unit, 18 Carrick Place, Mount Eden, Auckland 1024, New Zealand

j.miles-chan@auckland.ac.nz

+64 09 6301162

Abstract

Background: Low energy diets (LEDs) are effective for body weight (BW) loss and improvement of type 2 diabetes (T2D) risk biomarkers. Emerging evidence suggests that whole fruit feijoa powder, rich in polyphenols and abscisic acid, may further support T2D prevention. The FERDINAND study investigated whether daily consumption of a whole fruit feijoa powder enhanced LED-driven improvements in fasting plasma glucose (FPG), BW, and other metabolic markers during a 6-month intervention in adults with overweight and prediabetes.

Methods: At in-clinic screening 97 participants were enrolled into the trial and randomised to receive 1.15 g/day of whole fruit feijoa powder (Feiolix®, Fx, n=48) or Placebo treatment (n=49) for 6 months. All participants underwent 2-months of LED-induced weight loss, followed by 4 months of dietary advice for weight loss maintenance. FPG, BW and secondary outcomes including blood pressure (BP) and body composition, were assessed at 0 (baseline), 2 (post-LED), 4 and 6 months (end of study). Data was analysed using linear mixed-effects models as both raw/observed data (OD) and intention-to-treat (ITT) with imputation for missing not-at-random data points. Extreme outliers were removed prior to analyses. Statistical significance was set to $P \leq 0.05$.

Results: BW significantly decreased in both treatments during the 2 month LED, with rebound towards baseline by 6 months ($time_{0\text{-}6m}$: $P<0.001$), but with no difference between Fx and Placebo groups over the full intervention (treatment×$time_{0\text{-}6m}$, ns). FPG followed the weight loss trajectory and also decreased and rebounded in both treatment groups ($time_{0\text{-}6m}$: $P<0.001$), but the interaction between time and treatment over 6 months was significant (ITT: treatment×$time_{0\text{-}6m}$, $P=0.05$). At month 2 FPG was lower than baseline in both treatments, but at month 6 only Fx treatment remained significantly lower than baseline ($P<0.05$) and was also lower than Placebo ($P<0.05$). In some participants, FPG reverted to normal or worsened to T2D between enrolment and baseline assessment. When excluded, the sub-group with confirmed prediabetes showed similar outcomes for pattern of change in trajectory for Fx vs. Placebo treatment (ITT: treatment×$time_{0\text{-}6m}$, $P=0.04$) but with no significant difference between the two treatments at study end. Systolic BP (SBP), but not diastolic BP, also

changed significantly over 6 months between treatments (treatment×time$_{0\text{-}6m}$, OD: P=0.009, ITT: P=0.01), with SBP lower in Fx compared to Placebo at all timepoints (P<0.05). However, no difference between treatments was apparent in the sub-group of participants confirmed as normotensive at baseline (treatment×time, ns).

Conclusions: In adults with overweight and prediabetes, Fx supplementation may enhance improvements in glycaemia and blood pressure achieved through weight loss. The findings should be interpreted with some caution, given the influence in FERDINAND of individuals with FPG and blood pressure outside prediabetic and normotensive ranges. Nevertheless, these results warrant further investigation in larger cohorts at risk of T2D to fully evaluate the contribution that whole fruit feijoa powder can make to improved metabolic health.

Key Words: feijoa, polyphenols, abscisic acid, prediabetes, low energy diet, weight loss, type 2 diabetes prevention, FPG, blood pressure.

Introduction

Type 2 diabetes (T2D), which comprises 90-95 % of all diabetes cases (1), has become an ever-burgeoning strain on global health. An estimated 537 million adults worldwide currently have diabetes, with cases projected to reach 700 million by 2045 (2). Furthermore, the direct cost of T2D to the global economy went from USD 232 billion in 2007 to USD 966 billion in 2021, and is expected to exceed USD 1 trillion by 2030 (2). The number of individuals with prediabetes is even greater. Prediabetes is a state of dysglycaemia, whereby blood glucose levels are elevated above normal cut-offs, but below threshold for diabetes diagnosis. An estimated 860 million adults worldwide have prediabetes, with cases projected to exceed 1 billion by 2045 (2).

Therefore, implementing targeted T2D prevention, especially during prediabetes, is critical in alleviating global health burden. Extensive evidence points to excess adiposity being the biggest risk factor for T2D (3–10). This coupled with the increasing prevalence of obesity, makes body weight (BW) loss key in T2D prevention. Bariatric surgery and pharmaceutical agents are widely used for BW loss. However, these tools come with several drawbacks, such as limited availability and prohibitive costs. A less invasive method for achieving BW loss are commercial low (LED) and very low energy diets (VLED), implemented using nutritionally complete meal replacement products (11–13). LEDs encompass a daily energy intake between 3347-5021 kJ, while energy intake ≤3347 kJ characterises VLEDs (12,14). A large body of evidence shows that LEDs and VLEDs, combined with behavioural support, are effective for BW loss and improving T2D biomarkers (15–23).

Diet plays an important role in T2D, with risk reduction associated with increased intake of whole grains, fruits, vegetables, legumes and nuts, and lowered refined grain intake (24–26). Consequently, identifying foods which may enhance proven strategies, such as LEDs, is of great importance. Feijoa (*Acca sellowiana),* also known as pineapple guava, is a fruit originating in South America and widely grown in New Zealand (27,28), and is purported to lower T2D risk. It is abundant in polyphenols and abscisic acid (ABA), particularly in the skin (29,30). Evidence of polyphenols eliciting T2D risk reduction has been well established (31–42), with evidence for ABA emerging recently (43–

46). Mechanistically, ABA exhibits binding to pertussis toxin-sensitive G protein-coupled receptor (47), peroxisome proliferator-activated receptor gamma (48), and lanthionine synthetase C-like protein 2 (49,50). Activation of these targets promote intracellular signalling cascades involving cyclic adenosine monophosphate, cyclic adenosine diphosphate ribose and protein kinase B phosphorylation, which enhance insulin secretion, glucose uptake, and translocation of glucose transporter type 4 to the plasma membrane (51–56).

To-date, only two studies (1 pre-clinical, 1 clinical) have investigated the effect of feijoa on BW and T2D biomarkers. In leptin deficient ob/ob mice, whole fruit feijoa powder significantly decreased BW gain, liver organ weight and circulating total cholesterol (57). In a small sample, 12 week randomised control trial (RCT) of 34 adults with T2D, 150 mg/day of whole fruit feijoa powder significantly lowered fasting plasma glucose (FPG), glycated haemoglobin (HbA_{1c}) and triglycerides (TAG), compared to Placebo (58). We were interested in investigating the effect of whole fruit feijoa powder on glycaemic and associated metabolic outcomes in combination with acute weight loss and longer-term weight loss maintenance. The 6-month FERDINAND study investigated daily consumption of whole fruit feijoa powder during 2-months of LED-driven weight loss and 4-months of weight maintenance, in a multiethnic New Zealand cohort with overweight and prediabetes.

Methods

Study Design

As shown in Figure 1, the FERDINAND study was a two-arm, parallel design, double-blind RCT, of 6 months duration. Participants underwent 2-months of LED-driven weight loss (i.e. LED phase) followed by 4-months weight loss maintenance (i.e. maintenance phase). Participants consumed either whole fruit feijoa powder or Placebo powder every day for the entire study period. The whole fruit feijoa powder consisted of 1150 mg of microcrystalline cellulose and 1150 mg of freeze-dried powder with skin included (Feiolix®, Anagenix Ltd, Auckland, New Zealand; Fx). Meanwhile, the Placebo powder sachet contained 2300 mg of microcrystalline cellulose. The study received ethical approval from the

New Zealand Health and Disabilities Committee (Reference: 2022 EXP 12032) and was also prospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN: 12622000210774). The study was conducted at the Human Nutrition Unit (HNU), University of Auckland, New Zealand, from September 2022 to March 2024.

Participants

Prospective participants living in the wider Auckland area were pre-screened via an online questionnaire and telephone interview, then invited to the HNU for an on-site screening visit. Prior to any data collection, individuals provided written informed consent (New Zealand Health and Disabilities Ethics Committee; 2022 EXP 12032). Prediabetes status was determined by FPG, using American Diabetes Association guidelines (ADA, 5.6-6.9 mmol/L) (1). Hypertension was defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg (uncontrolled hypertension) and/or use of antihypertensive medications (controlled hypertension) (59,60). The other inclusion criteria were BMI ≥26 kg/m^2, BW ≤150 kg, Finnish Diabetes Risk Score ≥12, otherwise healthy per self-report and able to attend clinical investigation day (CID) visits. Potential participants were excluded if they had current or history of significant disease, including type 1 or type 2 diabetes mellitus, cardiovascular disease, pancreatic disease, digestive diseases (e.g. inflammatory bowel syndrome/disease, ulcerative colitis, Crohn's disease) and cancer, recent body weight loss/gain >10% within previous three months or were taking part in an active diet program, previous bariatric surgery, current medication controlling glycaemia and weight loss, steroid medications (except topical steroids) or atypical antipsychotics within previous three months, were intending to alter physical activity during following twelve months, smoked, vaped or used recreational drugs within previous six months and were pregnant or breastfeeding within previous six months. Additional exclusions included unwillingness to consume LED meal replacement products or adhere to the food avoidance requirements during the weight maintenance phase or hypersensitivities/allergies to these foods, non-compliance with the study protocol and participation in prior clinical intervention studies in the previous six months.

Randomisation and Blinding

Participants were randomly allocated in a 1:1 ratio to consume either Fx or Placebo powder, with the powders distinguished using anonymised codes and blinding conducted by an independent researcher who maintained confidentiality of the codes until the completion of the study. Participants and the study team remained blinded throughout the study period, and were unblinded upon completion of data collection.

Procedures

During the LED phase, participants consumed commercial complete meal replacement products (Cambridge Weight Plan, Corby, UK), whereby 4 energy-controlled sachets, each containing approximately 840 kJ, were consumed every day. Each meal replacement sachet was reconstituted using 250 mL of water only. Furthermore, participants consumed the intervention powder every day with their breakfast meal. Participants were prohibited from consuming all other foods or beverages during the LED phase, to ensure that any observed effects from bioactive compounds was from Fx, rather than other foods which may contain the same bioactive compounds. Upon completion of the LED phase, weight loss maintenance was monitored for four months whilst following healthy eating guidelines. Restrictions on food and beverage intake were mostly removed, with feijoa and feijoa-containing products the only prohibited items in this phase. Participants continued consuming their assigned intervention powder every day with their breakfast meal. Group diet advice sessions were conducted by registered dietitians at baseline and throughout the study. These sessions focused on compliance and providing educational content on healthy eating habits. The advice adhered to the New Zealand Ministry of Health healthy eating guidelines for improving metabolic health (61). For both intervention powders and meal replacement products, participants were instructed to keep all opened and unopened sachets and return them at their following CID visit. It was assumed that opened sachets equated to consumed sachets. Participants were instructed to contact the study team if sachets were opened but not consumed. Furthermore, participants were contacted regularly

throughout the study by a trained researcher, to discuss compliance. The following calculations were used to assess compliance:

$$\text{Meal replacement compliance (\%)} = \frac{100 \times \text{number of open meal replacement sachets returned}}{4\ \text{(sachets per day)} \times \text{number of days since baseline}}$$

$$\text{Intervention powder compliance (\%)} = \frac{100 \times \text{number of open intervention powder sachets returned}}{1\ \text{(sachet per day)} \times \text{number of days since last CID visit}}$$



Figure 1: FERDINAND Study Design.

<u>*Outcomes*</u>

BW and FPG were joint co-primary outcomes, while secondary outcomes comprised body composition, blood pressure and clinical blood markers. All outcomes were assessed at baseline and months 2, 4 and 6. Prior to BW and body composition measurements, participants were asked to remove shoes, heavy clothing, headwear (if applicable), jewellery and all items from their pockets. BW was measured in duplicate using a calibrated digital scale (Mettler Toledo Spider 2, Greifensee, Switzerland). Body composition was measured by dual energy x-ray absorptiometry (DeXA) using a Lunar iDXA scanner (GE Healthcare, Wisconsin, USA) and analysed using enCORE software (version 18, GE Healthcare, Wisconsin, USA). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using an automated Welch Allyn ProBP 2400 (Welch Allyn, New York, USA). Fasting venous

blood samples were collected into BD Vacutainer tubes (Becton, Dickinson and Company, New Jersey, USA). Plasma samples were collected for analysis of FPG in a fluoride oxalate tube. Whole blood was collected in a tripotassium ethylenediaminetetraacetic acid (K3-EDTA) tube for HbA_{1c} analysis. Serum samples were collected for lipid biomarkers using a serum separator (SST™ II Advance) tube. The following clinical blood markers were analysed on the cobas c 311 (Roche Diagnostics, Indianapolis, IN, USA): FPG, HbA_{1c}, total cholesterol, TAG, high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C).

Statistical analysis

Power calculations were conducted based on FPG as the primary outcome, using data obtained from the New Zealand arm of the PREVIEW diabetes prevention study (63), conducted in our laboratory in a cohort of adults with overweight and prediabetes, and of mixed ethnicity. The sample size calculations assumed that any FPG improvements achieved during LED phase would be maintained between the treatments during maintenance phase. In a two-arm, parallel-design longitudinal study with baseline FPG of 5.8 mmol/L (SD: 0.6 mmol/L), effect size of 0.5, type I error $\alpha = 0.05$, 80% power and two-tailed p-value, a clinically significant difference in FPG between treatments of 0.3 mmol/L was expected to be detected as statistically significant in a cohort of 160 participants (80 per treatment), including 20% drop out. Conduct of the trial during the COVID pandemic slowed recruitment however, and re-calculation of sample size showed that a group of n = 90 participants (45 per treatment) would still be expected to detect a change in FPG of 0.3mmol/L, with SD of baseline FPG 0.5 mmol/L, effect size of 0.6, type I error $\alpha = 0.05$, power of 80% as significant. Baseline characteristics were summarised using mean and standard deviation (SD) for continuous outcomes. Comparison of continuous outcomes, by treatment, were made using Welch's two-sample t-test. Pearson's chi-squared test with Yates' continuity correction was used for comparing categorical outcomes. Attrition rates between the treatments were compared using the likelihood ratio test. In participants who successfully completed the LED phase, compliance to the meal replacement was compared between treatments using Welch's two-sample t-test. In participants who successfully

completed the 6 month intervention, compliance to Fx and Placebo powders was also compared using Welch's two-sample t-test.

Analyses of all outcomes were conducted as repeated measures linear models (LM). Treatment arm (Fx, placebo), time (Month 0,2,4,6), treatment×time interactions, and gender were included as fixed effects, baseline measurement (month 0/CID1) included as covariates; AR(1) covariance structure applied within person. *Post hoc* multiple comparisons were conducted when the main effect was significant, using Bonferroni's adjustment. To determine robustness of LM outputs, all LM analyses were conducted using two approaches (sensitivity analysis):

i. Raw data (as observed), for all participants randomised into the trial at CID1, with no imputation for participant drop out.
ii. Intention To Treat (ITT), for all participants randomised into the trial at CID1, with imputation for missing-not-at-random data points using last value carried forwards (LVCF) methods.

Extreme statistical outliers (>3SD of the group mean) were excluded from the dataset and analyses. The level of significance was set at $P \leq 0.05$. Analyses were conducted in SPSS Statistics for Windows, version 29.0 (SPSS Inc., Chicago, IL, USA) and R, version 4.3.3 (R Foundation for Statistical Computing, Vienna, Austria).



Figure 2: Flow chart describing progress of participants through the trial. ITT cohort at m0 (baseline), n=97

Results

Baseline characteristics, attrition, and compliance

The baseline characteristics of the ITT population (n=97) are shown in Table 1. 81.4% of the population were female and 18.6% were male. Participants were ethnically diverse, with representation of European Caucasian (45.4%), Māori (17.5%), Pacific Peoples (18.6%), Asian Chinese (12.4%), Asian Indian (9.3%) and Other (16.5%) ethnicities. BW (mean ± SD) was 103.1 ± 21.0 kg and FPG was 6.21 ± 0.62 mmol/L. Comparison between the treatment arms showed that they were well matched, with no outcome significantly different at baseline. The percentage of participants who completed the study in the Fx and Placebo arms was 66.7% and 61.2% respectively. Attrition rates throughout the 6 month study were not significantly different between the treatments. Three quarters of withdrawals occurred during the LED weight loss phase (Figure 2). There was 1 adverse event (AE) reported in the Fx group during the LED, whereby the participant experienced intolerance to the meal replacement products. There was also 1 AE reported in the Placebo group during the LED, whereby intolerance to the placebo intervention powder was observed. These participants were subsequently withdrawn, upon review by the independent medical monitor. During the LED phase, in the cohort of completers at m2, >80% compliance to the meal replacements was achieved in both treatments. Compliance to Fx and Placebo throughout the 6 month study was also >80%, with higher compliance in Placebo (92 ± 11 %) vs Fx (82 ± 22 %; P=0.03).

Table 1: Baseline characteristics of ITT population, in all participants and by treatment.

	All participants (n=97)	Fx (n=48)	Placebo (n=49)	P-value
Demographics				
Age (yrs)	46.4 ± 10.1	46.5 ± 9.8	46.3 ± 10.4	0.93
Gender (Female:Male)	79:18	42:6	37:12	0.21
Primary Outcomes				
BW (kg)	103.1 ± 21.0	101.4 ± 21.6	104.7 ± 20.5	0.45
FPG (mmol/L)	6.21 ± 0.62	6.27 ± 0.68	6.16 ± 0.55	0.38
Secondary Outcomes				
SBP (mmHg)	132± 15	133 ± 17	132 ± 13	0.59
DBP (mmHg)	81 ± 8	80 ± 9	82 ± 8	0.36
TBFp (%)	45.3 ± 7.1	45.9 ± 7.0	44.7 ± 7.3	0.39
HbA_{1c} (mmol/mol)	40.7 ± 4.9	41.2 ± 5.0	40.2 ± 4.7	0.31
TC (mmol/L)	5.08 ± 1.09	5.04 ± 1.09	5.12 ± 1.09	0.70
TAG (mmol/L)	1.45 ± 0.58	1.47 ± 0.66	1.44 ± 0.49	0.80
HDL-C (mmol/L)	1.24 ± 0.24	1.27 ± 0.25	1.22 ± 0.22	0.31
LDL-C (mmol/L)	3.23 ± 0.93	3.17 ± 0.89	3.29 ± 0.97	0.54

Except gender, data is presented as mean ± SD. BW: body weight, FPG: fasting plasma glucose, Fx: whole fruit feijoa powder, SBP: systolic blood pressure, DBP: diastolic blood pressure, TBFp: total body fat percentage, HbA_{1c}: haemoglobin A1c, TC: total cholesterol, TAG: triglycerides, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol.

Primary outcomes – BW, FPG (all and sub-group)

BW: There was a significant change in BW between baseline and end of study/month 6, independent of treatment group, in both raw data and ITT populations (time, P<0.001, both), with a decrease as expected during the 2 month LED weight loss phase (Table 2, Figure 3A). In the ITT cohort, *post hoc* analyses revealed that BW remained significantly lower than baseline in both Fx and Placebo treatment groups at all subsequent timepoints over the 6 month intervention (P≤0.05, all). However, there was no significant interaction in the LM over 6 months and hence no significant difference in change in trajectory of BW between treatment groups in either the raw data (treatment×time, P=0.14) or ITT populations (treatment×time, P=0.85) respectively. Fx treatment did not result in significantly greater decrease in BW vs. Placebo over 6 months.

FPG, all: In the full cohort (n=97), there was also a significant change in FPG between baseline and end of study/month 6 independent of treatment group, in both raw data and ITT populations (Figure 3B, time, P<0.001, both), with a decrease during the LED weight loss phase. In the ITT population, *post hoc* analyses revealed that in the Fx treatment group FPG remained significantly lower than baseline at all timepoints (P≤0.05, all); as did Placebo at months 2 and 4 (P≤0.05, both) but not at month 6. In both

treatment groups FPG at month 6 was significantly higher than post-LED/month 2 ($P \leq 0.05$, both), indicative of rebound in both groups during the weight maintenance phase. FPG was significantly lower in Fx compared to Placebo treatment at month 6 ($P \leq 0.05$). Most notably, the interaction was borderline significant (treatment×time, P=0.06) for raw and statistically significant (treatment×time, P=0.05) for ITT populations respectively, reflecting a difference in change in trajectory of FPG between treatment groups over 6 months. Fx treatment did result in a significant decrease in FPG vs. Placebo over 6 months.

FPG, sub-group (pre-diabetes only): The mean (SD) delay between in-clinic screening/enrolment and baseline assessment was 33 (8) days. During this period, n=16 participants reverted to normo-glycaemia (FPG ≤5.5 mmol/L, Fx: n=8, Placebo: n=8) and n=12 participants worsened to T2D (FPG ≥7 mmol/L, Fx: n=9, Placebo: n=3). In analyses of the sub-group with confirmed prediabetes at baseline (n=69), the significant main effect of time on FPG independent of treatment group persisted in raw data and ITT populations (Figure 3C, time, $P<0.001$, both). *Post hoc* analyses in the ITT cohort showed a significant decrease during the LED weight loss phase in both treatments ($P<0.05$), a decrease from baseline to month 6 in the Fx treatment only ($P<0.05$); but notably no significant difference between Fx and Placebo treatments at end of study. Again, there was a significant interaction between treatment and time in the LM analyses both in raw (treatment×time, P=0.02) and ITT populations (treatment×time, P=0.04), reflecting the difference in trajectory of FPG (both decrease and increase) between the 2 treatment groups over 6 months. As with the full cohort, in this sub-group Fx treatment vs. Placebo resulted in different patterns of change in FPG over 6 months, but conversely with no evidence of a significant decrease in FPG below Placebo at any of the timepoints, including at month 6 end of study.

Secondary outcomes – BP (all and sub-group), TBFp, HbA_{1c}, lipids:

In both raw data and ITT populations there was a significant change between baseline and end of study/month 6, but independent of treatment group, for the majority of secondary outcomes: SBP, DBP, TBFp, HbA_{1c}, total cholesterol, TAG, HDL-C and LDL-C (time, $P<0.001$, all), with a consistent

decrease during the LED weight loss phase. *Post hoc* analyses in ITT cohort revealed that at post-LED/month 2, the following variables were significantly lower than baseline in both Fx and Placebo treatment: DBP, TBFp, HbA_{1c}, total cholesterol and LDL-C ($P \leq 0.05$, all). In the raw and ITT populations, LM analyses revealed no significant effects of Fx vs. Placebo treatment over the 6 month intervention for any of TBF, HbA_{1c} or lipids (Table 2, treatment×time, $P>0.05$, all).

SBP, DBP – Notably, however, there was a significant interaction between treatment and time in the LM for SBP, in both raw (treatment×time, P=0.009) and ITT populations (Figure 3D, treatment×time, P=0.01), reflecting the important difference in trajectory of SBP between treatment groups over 6 months. Conversely, there was no significant interaction for DBP over the 6 month intervention in either raw (treatment×time, P=0.28) or ITT cohorts (Table 2, treatment×time, P=0.23). *Post hoc* analyses in the ITT cohort also showed SBP to be significantly lower in Fx treatment compared to Placebo at all timepoints beyond baseline, i.e. months 2, 4 and 6 ($P \leq 0.05$, all). Fx treatment resulted in significantly greater improvement in SBP but not DBP vs. Placebo over 6 months.

BP, sub-groups: 47% of participants (Fx, n=24; Placebo, n=22) had hypertension at baseline. In the sub-group of normotensive participants, a significant change in SBP and DBP over 6 months, independent of treatment group, persisted in both raw data and ITT populations (Figure 3E, time, $P<0.001$, both). There was no significant decrease from baseline to the end of study in the Fx group or Placebo in either SBP or DBP; and for SBP alone there was a significant difference between the treatments at m6 ($P<0.05$). Contrary to the full cohort, however, in this smaller sub-group there was no significant interaction and hence no significant difference in the change in trajectory of SBP or DBP between treatment groups over 6 months in raw (treatment×time: SBP P=0.15, DBP P=0.52) or ITT populations (treatment×time: SBP P=0.15, DBP P=0.38). In this normotensive sub-group, Fx did not result in significantly greater decrease in SBP over 6 months.

Table 2: Primary and secondary outcomes in the ITT population (n=97).

	Fx (n=48)				Placebo (n=49)						
	Month 0	**Month 2**	**Month 4**	**Month 6**	**Month 0**	**Month 2**	**Month 4**	**Month 6**	**Time**	**Treat**	**Time x Treat**
Primary Outcomes											
BW (kg)	101.4 (3.12)	94.3 (3.09)[a]	95.5 (3.07)[a]	96.8 (3.08)[a,b]	104.7 (2.93)	97.3 (2.90)[c]	98.1 (2.89)[c]	99.0 (2.85)[c]	**<0.001**	0.64	0.85
FPG (mmol/L)	6.27 (0.10)	5.63 (0.09)[a]	5.92 (0.08)[a,b]	5.90 (0.08)[a,b,e]	6.16 (0.08)	5.72 (0.09)[c]	5.89 (0.07)[c]	6.03 (0.08)[d,e]	**<0.001**	0.13	**0.05**
Secondary Outcomes											
SBP (mmHg)	133 (3)	125 (2)[a,e]	126 (2)[a,e]	126 (2)[a,e]	132 (2)	129 (2)[e]	130 (2)[e]	132 (2)[e]	**<0.001**	**0.003**	**0.01**
DBP (mmHg)	81 (1)	75 (1)[a]	75 (1)[a,e]	77 (1)[a,e]	82 (1)	78 (2)[c]	80 (2)[e]	80 (2)[d,e]	**<0.001**	**0.014**	0.23
TBFp (%)	45.9 (1.0)	43.8 (1.1)[a]	43.7 (1.0)[a]	44.2 (1.0)[a]	44.7 (1.0)	42.6 (1.2)[c]	42.1 (1.2)[c]	42.4 (1.2)[c]	**<0.001**	0.65	0.40
HbA_{1c} (mmol/mol)	41.2 (0.7)	38.6 (0.6)[a]	39.5 (0.6)[a]	39.9 (0.6)[b]	40.2 (0.7)	37.9 (0.6)[c]	38.7 (0.5)[c]	39.2 (0.6)[d]	**<0.001**	0.84	0.95
TC (mmol/L)	5.04 (0.16)	4.49 (0.17)[a]	5.20 (0.18)[b]	5.09 (0.15)[b]	5.12 (0.16)	4.43 (0.16)[c]	5.18 (0.18)[d]	5.25 (0.19)[d]	**<0.001**	0.59	0.48
TAG (mmol/L)	1.42 (0.08)	1.30 (0.09)	1.36 (0.09)	1.44 (0.10)	1.44 (0.07)	1.29 (0.07)[c]	1.38 (0.09)	1.52 (0.09)[d]	**<0.001**	0.82	0.70
HDL-C (mmol/L)	1.27 (0.04)	1.19 (0.03)[a]	1.33 (0.05)[b]	1.39 (0.06)[a,b]	1.22 (0.03)	1.17 (0.03)	1.30 (0.04)[c,d]	1.30 (0.04)[c,d]	**<0.001**	0.86	0.25
LDL-C (mmol/L)	3.18 (0.13)	2.67 (0.14)[a]	3.20 (0.15)[b]	3.10 (0.12)[b]	3.29 (0.14)	2.62 (0.14)[c]	3.26 (0.16)[d]	3.30 (0.16)[d]	**<0.001**	0.66	0.28

Data presented as mean (SEM). Post hoc differences shown as superscripts; a: P≤0.05 compared to baseline in Fx arm, b: P≤0.05 compared to month 2 in Fx arm, c: P≤0.05 compared to baseline in placebo arm, d: P≤0.05 compared to month 2 in placebo arm, e: P≤0.05 between treatments at same timepoint. BW: body weight, FPG: fasting plasma glucose, Fx: whole fruit feijoa powder, SBP: systolic blood pressure, DBP: diastolic blood pressure, TBFp: total body fat percentage, HbA_{1c}: haemoglobin A1c, TC: total cholesterol, TAG: triglycerides, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol.



Figure 3: Linear mixed-effects model in the ITT population (n=97) for BW (A), FPG (B: all participants, C sub-cohort prediabetes confirmed at baseline) and SBP (D: all participants, E: sub-cohort normotension confirmed at baseline). Post hoc differences shown as superscripts; $: P≤0.05 compared to baseline in Fx arm, %: P≤0.05 compared to month 2 in Fx arm, #: P≤0.05 compared to baseline in placebo arm, &: P≤0.05 compared to month 2 in placebo arm, †: P≤0.05 between treatments at same timepoint. Data is presented as estimated mean ± SEM. BW: body weight, FPG: fasting plasma glucose, Fx: whole fruit feijoa powder, SBP: systolic blood pressure.

Discussion

The FERDINAND RCT investigated the effects of daily Fx supplementation on T2D biomarkers in a multi-ethnic cohort of adults following a 6 month weight loss dietary regime. Both Fx and Placebo groups lost similar amounts of body weight during the trial, with no detectable differential effects of the supplement. There were, however, significant improvements in glycaemia (FPG – all participants; and prediabetes sub-group) and blood pressure (SBP – all participants only; not normotensive sub-group) in the Fx group despite no difference in weight loss vs. Placebo.

Participants were enrolled into the intervention with overweight and dysglycaemia, and with a desire to achieve and maintain significant weight loss of ~8-10%. The intervention was successfully completed. There was 1 adverse event (AE) reported in the Fx group during the LED, whereby participant experienced intolerance to the meal replacement products. There was also 1 AE reported in the placebo group during the LED, whereby intolerance to the placebo intervention powder was observed. These participants were subsequently withdrawn, upon review by medical monitor. The study comprised an acute 2-month phase of LED-driven weight loss, followed by a 4-month phase of healthy eating lifestyle advice aiming to maintain the weight loss. Treatment arms were well matched at baseline, with no difference in any primary or secondary outcomes. Furthermore, compliance to both meal replacements and intervention powders was above 80% in both treatments. Regarding the primary outcomes, when analysed independent of treatment group, BW changed significantly over the 6 months as expected with a post-LED decrease over 2 months followed by rebound during the weight maintenance phase. BW was not significantly different between the treatments throughout the study, with no evidence of greater weight loss in the Fx treatment arm. However, despite similar weight loss, there was some evidence that Fx treatment did result in significantly greater decrease in FPG vs. Placebo over 6 months, as reflected in the change in trajectory between the 2 treatment groups over the full intervention; noting that effects were borderline significant. FPG was significantly lower than baseline in both treatments after 2-month LED, and remained lower than baseline at study

end in the Fx arm only. This suggests that Fx enhanced preservation of LED-driven improvements in FPG. However, these observations included 28 participants in whom FPG either reverted to normoglycaemia or progressed to T2D between the screening visit and baseline. Removal of these participants from analysis however did not fundamentally alter the outcome for FPG, despite the smaller sample size. Fx treatment significantly changed FPG when compared with Placebo over 6 months, both in all participants (n=97) which included individuals that had either spontaneously reverted to normoglycaemia or worsened to T2D at baseline and also in the smaller sub-group (n=69) of individuals confirmed to be within the International ADA prediabetes classification at baseline. It must be noted however, that in the smaller prediabetic subgroup, Fx treatment did not result in lower FPG than Placebo treatment at the end of study assessment, following 2 months of acute weight loss plus 4 months of weight loss maintenance.

Amongst the secondary outcomes, SBP in the Fx arm also significantly improved vs. Placebo over the 6 month intervention. Since there was no BP cut point at screening for exclusion from the trial, a large number of participants with overweight and associated biomarkers of poor metabolic health were identified with previously undiagnosed hypertension at baseline. When this sub-group were removed from the data analyses, the significant interaction between time and treatment was lost. Whilst this may be in part due the decrease in sample size, it is possible that the observed differences in SBP between the treatments may be driven by the sub-group of participants with (uncontrolled or controlled) hypertension.

The FERDINAND study is the first to investigate supplementation with a whole fruit feijoa powder for T2D prevention, but was not without some limitations. Owing to a number of challenges in recruiting participants into this study during the COVID pandemic, underpinned by many individuals with prediabetes being unaware of their adverse glycaemic status (64), and in the absence of validated predictive tools to pinpoint individuals with prediabetes amongst many with overweight yet normoglycaemia (65), the sample size was below the *a priori* target. Hence the study may not have detected small yet clinically important differences in FPG between treatments. Additionally, a sub-

group of participants reverted to normoglycaemia or progressed to T2D between enrolment and baseline assessment, with the average time between these visits being 33 days. Hence the cohort with confirmed prediabetes at baseline was smaller than planned. There was also a higher than predicted dropout rate during the 2 month LED. Overall, however, the FERDINAND study provides evidence to support Fx supplementation during weight loss for improvement in fasting glycaemia and systolic blood pressure in adults with overweight plus current/recent history of prediabetes. Further studies in larger cohorts are warranted to fully evaluate the contribution that whole fruit feijoa powder can make to improved metabolic health.

Declarations

Ethics approval and consent to participate: Ethics approval was received from the New Zealand Health and Disabilities Ethics Committee (2022 EXP 12032) and prospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN: 12622000210774). Study participants were provided with all study details, explained to them in writing and in person before they provided written informed consent.

Availability of data and materials: Not applicable

Competing interests: The authors declare no conflicts of interest.

Funding: This study was funded by the New Zealand National Science Challenge High Value Nutrition (NSC-HVN) Program, Ministry for Business, Innovation and Employment (MBIE, grant no. 3710040). The funders have no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions: IAM: Data collection, data analyses, manuscript preparation. IRSB: study conception, design and supervision, dietary formulation, data collection, data analyses, manuscript preparation; SDP: funding, study conception and design, dietary formulation, critical revision of manuscript, and co-senior author; JLMC: funding and principal investigator, study design and supervision, critical revision of manuscript, and co-senior author. All authors read and approved the final manuscript.

Acknowledgements: Anagenix Ltd. supplied the whole fruit feijoa powder (Feiolix®) for this study. We thank Dr Jia Jiet Lim for support during data collection; Registered Dietitians Dr Amy Liu and Shivaanee Ram for reviewing the diet design and administering group dietary consultation meetings with participants; Christine Keven at the Liggins Institute for blood marker measurements. We also appreciate the participants who took part in this study.

References

1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care. 2023 Jan;46(Suppl 1):S19–40.

2. International Diabetes Federation. IDF Diabetes Atlas: Tenth Edition. 10th edition. Brussels: International Diabetes Federation; 2021.

3. Abdullah A, Stoelwinder J, Shortreed S, Wolfe R, Stevenson C, Walls H, et al. The duration of obesity and the risk of type 2 diabetes. Public Health Nutr. 2011 Jan;14(1):119–26.

4. Ley SH, Schulze MB, Hivert MF, Meigs JB, Hu FB. Risk Factors for Type 2 Diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, et al., editors. Diabetes in America [Internet]. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 [cited 2024 Jun 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK567966/

5. Narayan KMV, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on Lifetime Risk for Diabetes in the U.S. Diabetes Care. 2007 Jun 1;30(6):1562–6.

6. Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients. 2015 Nov 13;7(11):9453–74.

7. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr. 2006 Aug;84(2):427–33.

8. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol. 2007 Feb 1;36(1):220–5.

9. Tchernof A, Després JP. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev [Internet]. 2013 Jan 1 [cited 2020 Jun 22]; Available from: http://journals.physiology.org/doi/abs/10.1152/physrev.00033.2011

10. Vazquez G, Duval S, Jacobs DR, Silventoinen K. Comparison of Body Mass Index, Waist Circumference, and Waist/Hip Ratio in Predicting Incident Diabetes: A Meta-Analysis. Epidemiol Rev. 2007 May 2;29(1):115–28.

11. Delbridge E, Proietto J. State of the science: VLED (Very Low Energy Diet) for obesity. Asia Pac J Clin Nutr. 2006;15 Suppl:49–54.

12. Gow ML, Pham-Short A, Jebeile H, Varley BJ, Craig ME. Current Perspectives on the Role of Very-Low-Energy Diets in the Treatment of Obesity and Type 2 Diabetes in Youth. Diabetes Metab Syndr Obes Targets Ther. 2021 Jan 18;14:215–25.

13. Mustajoki P, Pekkarinen T. Very low energy diets in the treatment of obesity. Obes Rev. 2001;2(1):61–72.

14. Saris WHM. Very-Low-Calorie Diets and Sustained Weight Loss. Obes Res. 2001;9(S11):295S-301S.

15. Parretti HM, Jebb SA, Johns DJ, Lewis AL, Christian-Brown AM, Aveyard P. Clinical effectiveness of very-low-energy diets in the management of weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2016;17(3):225–34.

16. Sellahewa L, Khan C, Lakkunarajah S, Idris I. A Systematic Review of Evidence on the Use of Very Low Calorie Diets in People with Diabetes. Curr Diabetes Rev. 2017;13(1):35–46.

17. Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022 Jan;65(1):14–36.

18. Astbury NM, Aveyard P, Nickless A, Hood K, Corfield K, Lowe R, et al. Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial. BMJ. 2018 Sep 26;k3760.

19. Astbury NM, Piernas C, Hartmann-Boyce J, Lapworth S, Aveyard P, Jebb SA. A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss. Obes Rev. 2019;20(4):569–87.

20. Noronha JC, Nishi SK, Braunstein CR, Khan TA, Blanco Mejia S, Kendall CWC, et al. The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2019 Mar 28;42(5):767–76.

21. Christensen P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, Martinez JA, Handjiev S, et al. Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab. 2018 Dec 1;20(12):2840–51.

22. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet. 2018 Feb;391(10120):541–51.

23. Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, Khatib NE, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020 Jun 1;8(6):477–89.

24. Imamura F, O'Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ. 2015 Jul 21;351:h3576.

25. InterAct Consortium, Romaguera D, Norat T, Wark PA, Vergnaud AC, Schulze MB, et al. Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct. Diabetologia. 2013 Jul;56(7):1520–30.

26. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and Management of Type 2 Diabetes: Dietary Components and Nutritional Strategies. Lancet Lond Engl. 2014 Jun 7;383(9933):1999–2007.

27. Sharpe RH, Sherman WB, Miller EP. Feijoa History and Improvement. Proc Fla State Hortic Soc. 1993;106:134–8.

28. Weston RJ. Bioactive products from fruit of the feijoa (*Feijoa sellowiana*, Myrtaceae): A review. Food Chem. 2010 Aug 15;121(4):923–6.

29. Faller ALK, Fialho E. [Polyphenol availability in fruits and vegetables consumed in Brazil]. Rev Saude Publica. 2009 Apr;43(2):211–8.

30. Rosendale D. Feiolix: The Pre-Diabetic Oppurtunity. 2020 Feb.

31. Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, Rosner B, et al. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women12345. Am J Clin Nutr. 2012 Apr 1;95(4):925–33.

32. Sun Q, Wedick NM, Tworoger SS, Pan A, Townsend MK, Cassidy A, et al. Urinary Excretion of Select Dietary Polyphenol Metabolites Is Associated with a Lower Risk of Type 2 Diabetes in Proximate but Not Remote Follow-Up in a Prospective Investigation in 2 Cohorts of US Women123. J Nutr. 2015 Jun;145(6):1280–8.

33. Zamora-Ros R, Forouhi NG, Sharp SJ, González CA, Buijsse B, Guevara M, et al. The Association Between Dietary Flavonoid and Lignan Intakes and Incident Type 2 Diabetes in European Populations. Diabetes Care. 2013 Dec;36(12):3961–70.

34. Rienks J, Barbaresko J, Oluwagbemigun K, Schmid M, Nöthlings U. Polyphenol exposure and risk of type 2 diabetes: dose-response meta-analyses and systematic review of prospective cohort studies. Am J Clin Nutr. 2018 Jul;108(1):49–61.

35. Delpino FM, Figueiredo LM. Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022 Jun 1;62(16):4465–80.

36. García-Martínez BI, Ruiz-Ramos M, Pedraza-Chaverri J, Santiago-Osorio E, Mendoza-Núñez VM. Hypoglycemic Effect of Resveratrol: A Systematic Review and Meta-Analysis. Antioxid Basel Switz. 2021 Jan 7;10(1):69.

37. Gu W, Geng J, Zhao H, Li X, Song G. Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Int J Clin Pract. 2022 Jan 31;2022:9734738.

38. Nyambuya TM, Nkambule BB, Mazibuko-Mbeje SE, Mxinwa V, Mokgalaboni K, Orlando P, et al. A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy. Mol Basel Switz. 2020 Nov 30;25(23):5645.

39. Gómez-Martínez S, Díaz-Prieto LE, Vicente Castro I, Jurado C, Iturmendi N, Martín-Ridaura MC, et al. Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. Nutrients. 2021 Dec 24;14(1):57.

40. Mollace V, Scicchitano M, Paone S, Casale F, Calandruccio C, Gliozzi M, et al. Hypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo- Controlled Study. Endocr Metab Immune Disord - Drug Targets. 2019 Feb 7;19(2):136–43.

41. Schell J, Betts NM, Lyons TJ, Basu A. Raspberries Improve Postprandial Glucose and Acute and Chronic Inflammation in Adults with Type 2 Diabetes. Ann Nutr Metab. 2019;74(2):165–74.

42. Sirvent P, Chavanelle V, Otero YF, Bargetto M, Le Joubioux F, Boisseau N, et al. TOTUM-63, a plant-based polyphenol-rich extract, improves glycaemic control in subjects with prediabetes or

early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2022 Dec;24(12):2331–40.

43. Ameri P, Bruzzone S, Mannino E, Sociali G, Andraghetti G, Salis A, et al. Impaired increase of plasma abscisic Acid in response to oral glucose load in type 2 diabetes and in gestational diabetes. PloS One. 2015;10(2):e0115992.

44. Atkinson FS, Villar A, Mulà A, Zangara A, Risco E, Smidt CR, et al. Abscisic Acid Standardized Fig (Ficus carica) Extracts Ameliorate Postprandial Glycemic and Insulinemic Responses in Healthy Adults. Nutrients. 2019 Jul 31;11(8):1757.

45. Magnone M, Ameri P, Salis A, Andraghetti G, Emionite L, Murialdo G, et al. Microgram amounts of abscisic acid in fruit extracts improve glucose tolerance and reduce insulinemia in rats and in humans. FASEB J. 2015 Dec;29(12):4783–93.

46. Magnone M, Leoncini G, Vigliarolo T, Emionite L, Sturla L, Zocchi E, et al. Chronic Intake of Micrograms of Abscisic Acid Improves Glycemia and Lipidemia in a Human Study and in High-Glucose Fed Mice. Nutrients. 2018 Oct 12;10(10):1495.

47. Bruzzone S, Moreschi I, Usai C, Guida L, Damonte G, Salis A, et al. Abscisic acid is an endogenous cytokine in human granulocytes with cyclic ADP-ribose as second messenger. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5759–64.

48. Bassaganya-Riera J, Guri AJ, Lu P, Climent M, Carbo A, Sobral BW, et al. Abscisic Acid Regulates Inflammation via Ligand-binding Domain-independent Activation of Peroxisome Proliferator-activated Receptor γ. J Biol Chem. 2011 Jan 28;286(4):2504–16.

49. Sato M, Dehvari N, Oberg AI, Dallner OS, Sandström AL, Olsen JM, et al. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes. 2014 Dec;63(12):4115–29.

50. Zeng M, van der Donk WA, Chen J. Lanthionine synthetase C–like protein 2 (LanCL2) is a novel regulator of Akt. Mol Biol Cell. 2014 Dec 1;25(24):3954–61.

51. Charles MA, Fanska R, Schmid FG, Forsham PH, Grodsky GM. Adenosine 3′,5′-Monophosphate in Pancreatic Islets: Glucose-Induced Insulin Release. Science. 1973;179(4073):569–71.

52. Furman B, Pyne N. Modulation of cyclic nucleotides and cyclic nucleotide phosphodiesterases in pancreatic islet beta-cells and intestinal L-cells as targets for treating diabetes mellitus. Curr Opin Investig Drugs Lond Engl 2000. 2006 Oct;7(10):898–905.

53. Islam MdS. The Ryanodine Receptor Calcium Channel of β-Cells: Molecular Regulation and Physiological Significance. Diabetes. 2002 May 1;51(5):1299–309.

54. Sharp GWG. The Adenylate cyclase-cyclic AMP system in islets of langerhans and its role in the control of insulin release. Diabetologia. 1979 May 1;16(5):287–96.

55. Takasawa S, Tohgo A, Noguchi N, Koguma T, Nata K, Sugimoto T, et al. Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J Biol Chem. 1993 Dec 15;268(35):26052–4.

56. Zocchi E, Hontecillas R, Leber A, Einerhand A, Carbo A, Bruzzone S, et al. Abscisic Acid: A Novel Nutraceutical for Glycemic Control. Front Nutr. 2017;4:24.

57. Foo LY, Watson RR. Feijoa Fruit Extract [Internet]. 2013 [cited 2023 Jan 6]. Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2013186680

58. Taghavi M, Hoseyni R, Panah HR, Razavi M, Watson R. Effect of Feijoa Supplementation in Patients with Type 2 Diabetes. Iran J Endocrinol Metab. 2012;14(3):222–5.

59. Iqbal AM, Jamal SF. Essential Hypertension. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Apr 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539859/

60. World Health Organization. Hypertension. 2023 [cited 2025 Apr 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension

61. McIntyre L, Anna Jackson, Carr H, Carter MA, Mackay S, Gerritsen S. Eating and activity guidelines for New Zealand adults. Updated 2020. Wellington, New Zealand: Ministry of Health; 2020.

62. DeMers D, Wachs D. Physiology, Mean Arterial Pressure. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Aug 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538226/

63. Fogelholm M, Larsen TM, Westerterp-Plantenga M, Macdonald I, Martinez JA, Boyadjieva N, et al. PREVIEW: Prevention of Diabetes through Lifestyle Intervention and Population Studies in Europe and around the World. Design, Methods, and Baseline Participant Description of an Adult Cohort Enrolled into a Three-Year Randomised Clinical Trial. Nutrients. 2017;9(6):632.

64. Centers for Disease Control and Prevention. Diabetes. 2024 [cited 2025 May 15]. National Diabetes Statistics Report. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html

65. Barber SR, Davies MJ, Khunti K, Gray LJ. Risk assessment tools for detecting those with pre-diabetes: a systematic review. Diabetes Res Clin Pract. 2014 Jul;105(1):1–13.